Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
Using a 1mm derma roller every day with nanoxidil is not recommended; it should be used once a week. The user had no initial instructions and used it nightly for two months.
Hair loss treatments, ranging from topical minoxidil and finasteride to taking hormones such as estradiol or nandrolone, as well as a controversial suggestion of an orchiectomy. A hair system is also mentioned as an alternative solution.
The post discusses using microneedling alone for hair regrowth without finasteride or minoxidil due to side effects and dependency concerns. The user is also considering the "Zix" formula, acetic acid, topical zinc solutions, and lithium chloride.
Bryan Johnson uses topical dutasteride, minoxidil, and microneedling for hair loss. Users discuss treatment effectiveness and side effects, debating topical versus oral dutasteride efficacy.
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
The post is about a user's progress with using finasteride, minoxidil, and dermarolling for hair loss. The conversation includes comments about different treatments and methods used.
The conversation discusses impressive results from a 28-day application of a hair loss treatment. Users compare it to their experiences with Minoxidil and Dutasteride, noting excitement over the new findings.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
Redensyl improved hair thickness slightly with no side effects, but no regrowth. Minoxidil provided significant regrowth but caused facial side effects like puffiness.
Pyrilutamide/KX-826 is being discussed for its effectiveness in hair regrowth, with some users reporting positive results, especially in early hair loss cases. Users have combined it with treatments like Minoxidil, and some experienced initial shedding before seeing regrowth.
The conversation is about someone's 2-month hair regrowth progress using topical minoxidil and finasteride combined with 0.5mm dermarolling, started 3 months ago. They did not provide a baseline picture from the start date.
The conversation discusses whether dermarolling (microneedling) works with oral minoxidil for hair loss treatment. References to studies on microneedling alone and combined with minoxidil are provided.
PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.
Researching whether pyri and enza, which are stereoisomers of each other, share the same features related to CNS penetration/GABA Inhibition; safety and efficacy when used topically at 0.5-1%; and cost comparison between the two treatments.
The conversation is about a user interested in participating in hair cloning clinical trials due to their fine hair and previous positive experience with clinical trials. They are seeking information on how to volunteer for such trials.
Significant hair regrowth was achieved using 1 mg Finasteride, 5% Minoxidil, and dermarolling, with a switch from a 0.5 mm to a 1 mm roller after two months. The user is happy with the results but is still considering a hair transplant for more density.
Using a dermaroller with topical minoxidil and oral finasteride regrows hair and improves temple areas. Users highlight the benefits of microneedling tools and stress the importance of consistency and proper sanitation.
The post and conversation are about a hair loss treatment stack without finasteride or dutasteride. The suggested treatments include Alfatradiol, Koshine826, Ketoconazole lotion, Minoxidil, microneedling, Tretinoin, and Stemoxydine.
The user experienced side effects from low-dose topical finasteride and is considering using clascoterone (CB-03-01) despite concerns about its risks and cost. They seek advice on its effectiveness and potential side effects compared to other treatments like alfatradiol and fluridil.
PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.
The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.
The user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and ask for advice on shipping within the EU and product quality, while also mentioning their current hair loss treatment involves mixing RU with Stemoxydine and Alfatradiol.
The conversation discusses the effectiveness of pyrithione zinc and GT20029 for hair loss. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The user is experiencing hair regrowth with oral minoxidil and dutasteride but still has fragile hairs that easily pluck out from the front center. Despite improvements, the user is concerned about the persistent fragility and shedding of these hairs.
PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.
The conversation discusses disappointment over only receiving a financial report from Cassiopea instead of trial results for Breezula/CB-03-01, a hair loss treatment. However, there is optimism as the company is advancing Breezula into Phase III trials for men, starting trials for women, and submitting an NDA for their acne product, Winlevi.